BioNTech is a German biopharmaceutical company known for its focus on developing and manufacturing immunotherapies for cancer and other serious diseases. Founded in 2008, BioNTech gained significant public attention for its work on mRNA technology, particularly in the creation of a COVID-19 vaccine in partnership with Pfizer. This vaccine was among the first to receive emergency use authorization globally. The company leverages its innovative technology platform to create personalized cancer treatments and has been involved in various clinical trials for different therapeutic areas. BioNTech aims to harness the power of the immune system to fight diseases, employing techniques such as messenger RNA (mRNA) to instruct cells to produce proteins that can trigger an immune response.
BioNTech transitions focus from COVID-19 vaccines to pioneering mRNA-driven cancer therapies, amid reduced vaccine demand. Latest earnings reveal a profit of €1.08 per share, exceeding expectations but down from previous…